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Hyaluronan (HA) is abundantly expressed in several human tissues and a variety of roles for HA has been highlighted.
Particularly relevant for tissue repair, HA is actively produced during tissue injury, as widely evidenced in wound healing
investigations. In the heart HA is involved in physiological functions, such as cardiac development during
embryogenesis, and in pathological conditions including atherosclerosis and myocardial infarction. Moreover,
owing to its relevant biological properties, HA has been widely used as a biomaterial for heart regeneration
after a myocardial infarction. Indeed, HA and its derivatives are biodegradable and biocompatible, promote
faster healing of injured tissues, and support cells in relevant processes including survival, proliferation, and
differentiation. Injectable HA-based therapies for cardiovascular disease are gaining growing attention because
of the benefits obtained in preclinical models of myocardial infarction. HA-based hydrogels, especially as a vehicle
for stem cells, have been demonstrated to improve the process of cardiac repair by stimulating angiogenesis, reducing
inflammation, and supporting local and grafted cells in their reparative functions. Solid-state HA-based scaffolds have
been also investigated to produce constructs hosting mesenchymal stem cells or endothelial progenitor cells to be
transplanted onto the infarcted surface of the heart. Finally, applying an ex-vivo mechanical stretching, stem cells grown
in HA-based 3D scaffolds can further increase extracellular matrix production and proneness to differentiate into
muscle phenotypes, thus suggesting a potential strategy to create a suitable engineered myocardial tissue for
cardiac regeneration.
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Hyaluronan (or hyaluronic acid, HA) is a naturally occur-
ring polysaccharide widely distributed from lower organ-
isms, such as bacteria [1,2], to complex eucariotes [3].
Together with collagen, HA is one of the most abundant
component of the extracellular matrix (ECM). It is a
non-sulfated, high molecular-weight glycosaminogly-
can composed of repeating polymeric glucuronic acid
and N-acetyl-glucosamine disaccharides conjugated by
a glucuronidic β(1→ 3) bond and hexosaminidic β(1→ 4)
linkages [4]. The polymeric structure of HA contains up
to 25,000 disaccharide repeats in length and reaches a
molecular weight of ~4,000 kDa. In cells, HA is pro-
duced by membrane-bound synthases (HAS-1 [5], HAS-2
[6], HAS-3 [7]) at the inner surface of plasma membrane* Correspondence: claudio.muscari@unibo.it
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unless otherwise stated.and the chains are released in the ECM through pore-like
structures.
The hydrolysis of the linkage between N-acetyl-
glucosamine and glucuronic acid residues, thus HA deg-
radation, is driven by hyaluronidases (hyaluronidases 1-5
and HYALP1), that also hydrolyze the glycosidic bonds of
chondroitin and dermatan sulfates [8].
HA is present in ECM both in a soluble form and cova-
lently bond to a variety of proteins such as proteoglycans
(brevican, neurocan, versican) [9] and SHAP (serum-derived
hyaluronan-associated protein) [10], often referred to
as hyaladherins. Moreover, HA forms reversible linkages
with water giving a specific contribution to lubrication
and strength in compression in joints and soft tissues [11].
HA is also the ligand of several membrane receptors
activating intracellular signaling cascades. Among them
are CD44, RHAMM (receptor for hyaluronan-mediated
motility expressed protein), LYVE-1 (lymphatic vessel
endothelial hyaluronan receptor-1), HARE (hyaluronanLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[13]. CD44 is the major cell surface HA receptor,
although it can bind also other ECM proteins, growth
factors, and cytokines [14]. Most cells express CD44,
including fibroblasts, smooth muscle cells, epithelial
cells, and immune cells such as neutrophils, macro-
phages, and lymphocytes. HA-CD44 interactions play
an essential role by modulating cellular growth, develop-
ment, adhesion, and migration activities. Mainly through
Toll-like receptors, fragmented HA is also involved in
the regulation of inflammation and in immunological
processes [15].
In humans, HA is abundantly expressed in several tis-
sues and its different roles have been extensively reviewed,
with special emphasis about those related to angiogenesis
[16] and cancer [17]. HA is actively produced upon tissue
injury and is significantly involved in tissue repair [18,19].
Under these conditions, HA is more polydisperse, frag-
mented, with a preponderance of lower-molecular-mass
forms. Low-sized fragments of HA (LMW, 100-500 kDa),
but not the native high-molecular-mass HA molecules
(HMW, ~4,000 kDa), stimulate inflammatory cells [20,21].
Monocytes, macrophages, and dendritic cells migrate and
home in damaged tissues thanks to the LMW stimulation
of Toll-like receptors and the induction of cytokines and
chemokines. These receptor-activated signaling cascades
involve the nuclear factor kappa-light-chain-enhancer of
activated B cells (NF-kB)/matrix metalloproteinases
(MMPs) system and myeloid differentiation primary
response gene (MyD88) [22] (Figure 1). LMW can also
induce fibroblasts and myofibroblasts to proliferate and
generate a fibrotic scar via a synergic CD44 and growth
factors receptor (GFsR) -mediated signal transduction.
Specifically, the ERM (ezrin, radixin and moesin) protein
family/merlin system has been described to be responsible
of increased cell proliferation through the organization
of actin and other cytoskeletal proteins that, in turn,
activate extracellular signal-regulated protein kinases 1
and 2 (ERK1/2) leading to the enhanced expression of
cell cycle proteins [23].
LMW can also be considered as proangiogenic factors
[24]. Indeed, vascular endothelial cells (ECs) and vascu-
lar smooth muscle cells (VSMCs) express both CD44
and RHAMM receptors and can interact with LMW
stimulating both Ras/Raf/ERK1/2 and protein kinase C
(PKC) pathways, then promoting cell migration, prolifer-
ation, and vessel formation [25] (Figure 1). Native HA
exerts opposite effects because of its antiangiogenic
properties and the block of the proinflammatory effects
of LMW [26]. It has been suggested that HMW can clus-
ter HA receptors whose intracellular signaling is different
from that induced by LMW [27]. Native HA presumably
activates a protein phosphatase (PP) that dephosphory-
lates ERM and merlin, the latter inhibiting the Ras/ERK1/2 pathway [23]. Cell survival can also be improved by
native HA, e. g. through phosphoinositide 3-kinase (PI3K)/
Akt stimulation downstream of CD44 [27] (Figure 1).
The molecular size of HA influences its activity in
neoplastic cells. For example, only 6- to 40-mers, but
not native HA, can induce CD44 cleavage [28], promote
tumor cell motility in a CD44-dependent manner [29],
or activate MMPs [30].
HA is abundant in the heart where it is involved in
physiological functions, such as cardiac development
during embryogenesis [31], and in pathological condi-
tions including atherosclerosis [32] and myocardial in-
farction (MI) [33]. In the infarcted region a significant
inflammatory reaction increases CD44 expression in in-
filtrating leukocytes, wound myofibroblasts, and vascular
cells [34]. It is known that cardiac healing after a MI is
paralleled by connective tissue replacement resulting in
a scar. During this process an early increase of HA can
be detected in the injured tissue [33]. The amount of
water also gradually increased and correlated with HA
accumulation. After about one month the scar was well
formed and only six months later the HA content began
to decrease [35]. Although these changes serve at redu-
cing the risk of wall rupture, they usually predispose to
pathological left ventricle (LV) remodeling and heart
failure [36].
Review
Chemically modified HA for tissue engineering
applications
Due to the poor mechanical properties of native HA,
the clinical use of the unmodified molecule is generally
limited to viscosurgery applications. Thus, several ap-
proaches are followed to improve the structural fea-
tures of HA by providing chemical modifications to
the HA molecule [37].
The most common structural changes in HA derive
from crosslinkings performed under either acidic, neu-
tral or alkaline conditions [38]. HA autocrosslinking oc-
curs in the absence of potentially toxic crosslinkers and
produces hydrogels through quite simple reactions.
Despite the electrostatic repulsion due to its negative
groups, HA can autoaggregate via hydrophobic inter-
actions and/or hydrogen bonds between acetamido
and carboxylate groups [39]. These non-covalent inter-
actions are rather weak, so the aggregate easily forms
and dissociates, depending on temperature and other
environmental conditions.
Besides autocrosslinkable HA, other HA hydrogels
employed in tissue engineering have been produced
through added crosslinkers. More stable crosslinked
HA can be obtained by means of S-S bridges, using
HA-benzoyl cystein derivatives [40]. Adipic dihydrazide
has also been frequently conjugated to HA through its
Figure 1 Schematic model showing the possible receptor-mediated signal transduction pathways through which HA of different molecular
weights can modulate cell functions. High molecular weight-HA (HMW) and low molecular weight-HA (LMW) differently modulate receptor-mediated
cell functions. Endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) interacting with LMW can promote angiogenesis via CD44 and
RHAMM transduction signaling leading to increased cell migration, cell proliferation, and tube formation. Inflammatory cells (ICs), such as
monocytes/macrophages and dendritic cells, are stimulated by LMW through Toll-like receptor-2 and Toll-like receptor-4 (TLR-2, TLR-4) that
promote cell migration, recruitment, and homing in damaged tissues. LMW, through CD44 and growth factors receptors (GFsR), can also induce
fibroblasts and myofibroblasts (MFs) to proliferate and generate a fibrotic scar. ERM (ezrin, radixin, and moesin) protein family/merlin system seems to
be largely involved in the interplay between LMW and GFs. Specifically, a non-yet identified GF-stimulated protein kinase (PK) phosphorylates ERM and
promotes its migration from the cytoplasm to CD44 with consequent re-arrangement of cytoskeletal proteins that leads to cyclin D1 overexpression
and increased cell proliferation. HMW exerts opposite effects, due to its antiangiogenic and antifibrotic action, at least through the activation of a
CD44-dependent protein phosphatase (PP). It has been hypothesized that HMW can induce the formation of HA-receptor clusters whose signal
transduction pathways are different from those stimulated by single and separated HA-receptors interacting with LMW. HMW is also involved in
cell survival through the stimulation of PI3K/Akt downstream of CD44.
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[41]. Water insoluble gels have been produced by crosslink-
ing HA with glutaraldehyde (GTA), likely through hemiace-
tal linkages [42]. The crosslinking of the hydroxyl groups of
HA using divinylsulfone provides resistant gels (hylans)
through a very fast reaction in alkaline solution [43]. HA
crosslinking with carbodiimides starts instead through a
first reaction with carboxyl groups to form anhydrides
that then interact with the hydroxyl groups. Specific-
ally, 1-ethyl-3-(3-dimethyl aminopropyl)carbodiimide
(EDC) has been widely used for this purpose, giving eitherbiocompatible scaffolds of crosslinked HA [44] or HA
conjugated with collagen or other glycosaminoglycans
[45,46]. Crosslinked HA-based scaffolds suitable for
further molecular modifications have been produced
with polyfunctional epoxides forming ester and ether
bonds [47].
Differently from the aforementioned pre-formed chem-
ically modified HA biomaterials, some HA-derivatives
show to be crosslinked in situ. Such materials are in a
cooled liquid form during their injection into soft tissues,
hence reducing the damage due to the filling maneuver,
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temperature [48]. Light-based systems have been also
described to produce photopolymerizable HA [49].
Other HA conjugates have been employed for tissue
engineering applications. For example, different degrees
of esterification of the HA carboxylic groups with several
types of alcohols have allowed the production of both
woven and non-woven meshed scaffolds with a variety
of degradation times and strength resistance [50]. When
HA is oxidized to form a dialdehyde, it can react with
amino groups giving rise to Schiff bases, as described for
HA-chitosan conjugates [51].
Finally, new drugs can be produced through different
functionalizations of the HA side groups. One of the
earliest HA derivatives with pharmacological properties
is a HA sulfate ester showing heparin-like anticoagulant
activity and high resistance to hyaluronidase [52]. An-
other example is a superoxide-dismutase HA-conjugate
exerting anti-inflammatory activity through its antioxi-
dant activity [53]. Butyrate and retinoate have also been
esterified with HA hydroxyl groups to provide pro-
differentiating properties towards grafted stem cells [54]
(Figure 2).
Despite the above-mentioned modifications, HA-based
materials maintain most of the biological properties ofFigure 2 HA structure and sites of modification. The
disaccharide repeat units of HA are shown with the primary sites for
chemical modifications generally used for tissue engineering
applications. The hydroxyl groups of HA form covalent linkages such
as ether, esters, and hemiacetal bonds. The carboxyl groups can
form ether, anhydride, and carbamide bonds, while Schiff bases
can originate from HA dialdehyde reacting with amino groups.
Some HA adducts commonly employed in regenerative medicine
are also shown.native HA, useful for tissue regeneration. Scaffolds in form
of HA-hydrogels, -sponges, or -meshes [55] usually:
a) are biodegradable, biocompatible, and
bioresorbable [56];
b) improve functions such as lubrication, cell
differentiation, and cell growth [4];
c) have potential to provide faster healing and repair of
chronic wounds [57];
d) exhibit low non-specific adsorption of proteins
[9,10] and specific with cell receptors [12] to enhance
tissue growth and repair.
Treatment of the infarcted heart with HA-based
biomaterials
HA-based hydrogels without cellular components
Several studies show that injectable HA-based hydrogels
are rather effective in regenerating the damaged cardiac
tissue after a MI. Yoon et al. induced a MI in rats via
circumflex artery ligation and an acrylated HA hydrogel,
obtained using a polyethylenglycol-thiol (PEG-SH4) cross-
linker, was injected into the epicardium of the infarcted
region [58]. A significant decrease in both infarcted area
and apoptotic index followed the treatment with the
hydrogel, while the number of arterioles and capillaries
increased. Parameters of heart function, such as ejection
fraction, dP/dt max, and dP/dt min also improved in
treated animals. When 50 kDa, 130 kDa, and 170 kDa
HA-based hydrogels were applied to the infarcted area in
a sub-acute model of MI, the lowest sized hydrogel pro-
vided the most significant myocardial regeneration and
functional recovery of the heart. Conversely, independ-
ently of the HA size, cardiac regeneration did not occur in
a chronic model of MI, reflecting that the injection timing
of the therapeutic agents is also a major determinant in
the process of cardiac repair [59]. Thus two major factors,
i.e. molecular weight of HA and progression of MI, are
responsible for HA-dependent regeneration in MI.
HA-based hydrogels with different degradation times
were produced by Tous et al. [60]. Two hydrolytically
degrading 66 kDa HA hydrogels (~3 and 10 weeks, re-
spectively), with low and high degree of crosslinking
(low: ~7 kPa; high: ~35-40 kPa), and two more stable
HA hydrogels with similar low and high initial mechan-
ics, were evaluated in an ovine model of MI. The most
stable hydrogels were obtained using metacrylate to
form crosslinkable macromers. LV wall thickness in-
creased in the infarcted area injected with all hydrogels
compared to the untreated controls and the most stable
HA maintained the wall thickness longer than the hy-
drolytically degrading hydrogels. Moreover, while both
HA with high mechanics initially reduced LV volumes,
only the most stable hydrogel with high mechanics was
more effective after a longer period, implying that wall
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ance. Consistently with the regeneration effects induced
by HA, the injection of these HA-hydrogels resulted in
better cardiac output values than those observed in the
untreated infarcted hearts. A computational study inves-
tigating the mechanical properties in myocardium after
HA hydrogel injection [61] argued that this treatment
can enhance the stiffness of the myocardium/hydrogel
composite region in an anisotropic manner and increase
the modulus in the longitudinal direction compared to
control myocardium. In these simulations, the overall
increased stiffness, in combination with the augmented
volume due to hydrogel injection, partially reduced the
global fiber stress.
Taken together, these results show that a relevant
mechanism underlying the benefits induced by HA-based
hydrogels is attributable to their bulking (thickening) and
stabilizing effects on the infarcted region. Fiber stress in
the injured myocardium can be thoroughly decreased de-
pending on hydrogel stiffness, that is regulated by its own
mechanical properties and degradation behavior. Fur-
thermore, these findings support the notion that small
HA fragments exert opposite effects than longer HA
molecules by promoting angiogenesis. Interestingly, the
addition of VEGF to 50 kDa HA fragments did not further
increase vessel density in the infarcted area, underlining
the great efficacy of low molecular weight HA in stimulat-
ing the process of vascularization.
In the attempt to obtain a sustained delivery system,
Purcell et al. developed in situ forming HA hydrogels
with degradable crosslinks to regulate the release of both
recombinant stromal cell-derived factor-1α (rSDF-1α)
and HA fragments to the injured myocardium [62]. This
strategy was adopted in order to enhance the homing of
circulating bone marrow cells in the myocardium follow-
ing a MI. A degradable 74 kDa HA with hydroxyethyl-
methacrylate (HeMA) functionality was formed as a
crosslinkable hydrogel upon a brief visible light exposure
using a chemical initiator system. The diffusion of the
encapsulated rSDF-1α was slow because of the electro-
static interactions between the negative-charged carbox-
ylic groups of the HeMA-HA and the positive-charged
basic aminoacid residues exposed on the external do-
mains of the chemokine. The release of both rSDF-1α
and crosslinked HA was sustained for over seven days
and these compounds stimulated in vitro bone marrow
cell chemotaxis through CXCR4 and CD44 receptors,
respectively. Moreover, the homing of circulating mar-
row cells significantly increased in the infarcted region
injected with the HeMA-HA hydrogel plus rSDF-1α,
compared to rSDF-1α or HeMA-HA alone. The binding
of HA to CD44 stimulated G-protein-dependent bone
marrow cell motility through Rho-associated protein kin-
ase (ROCK) signaling [63] and cell adhesion throughintegrin expression [64]. A fluorophore-conjugated SDF-
1α analogue was also associated to 74 kDa HA and chem-
ically modified with HeMA to form a hydrolytically
degradable hydrogel only at body temperature [65]. In this
study HA gelation was rapidly induced in vivo through a
free-radical initiator system. HA hydrogel degradation, to-
gether with the complete release of the SDF-1α analogue,
took more than one month. The mixed SDF-1α analogue/
HA hydrogel injected into rat cardiac border zone signifi-
cantly improved vascularity, ventricular geometry, ejection
fraction, cardiac output and contractility. According to a
similar strategy, the release of recombinant tissue-inhibitor-3
of matrix metalloproteinase (TIMP-3) from a degradable
HA hydrogel counteracted pathological LV remodeling after
experimental MI. This effect was due to a marked reduction
in pro-inflammatory cytokines as a consequence of the
sustained delivery of TIMP-3 in the border zone [66].
Another set of experiments carried out by Ventura
et al. explored the effects of HA-mixed ester of retinoic
acid and butyric acid, alone or in combination with stem
cells, on cardiovascular repair and functional recovery
[54,67,68]. All-trans retinoic acid and butyric acid were
conjugated with 85 kDa HA providing mixed HA esters.
Their general formula consisted of three distinct dimeric
repeating units, two of them are retinoylate or butyrylated
in the hydroxyl group of the N-acetyl-D-glucosamine
residues, usually in position 6, whilst the third unit is
non-substituted. The number of the esterified OH groups
for each disaccharide unit of HA (degree of substitution,
DS) ranged between 0.002 and 0.1 with retinoic acid and
between 0.05 and 1.5 with butyric acid. HA-mixed esters
were previously demonstrated to afford high throughput
of cardiogenesis in embryonic stem cells [69]. Indeed,
CD44 is abundantly expressed in the embryonic myocar-
dium and the differentiation process is accompanied by an
increased expression of CD44 [70]. Positron emission
tomography (PET) showed that HA-mixed esters with DS
of retinoic acid and butyric acid of 0.032 and 1.44, respect-
ively, injected alone in the infarcted rat heart, restored
cardiac [18 F]fluorodeoxyglucose uptake as well as in-
creased both capillary density and recruitment of endogen-
ous Stro-1-positive stem cells [67]. The stimulation of
vascularization was likely the consequence of the enhanced
gene expression and secretion of VEGF and HGF from
stem cells exposed to the HA-mixed ester. Treated hearts
also exhibited a decrease in the number of apoptotic cardi-
omyocytes, due to putative enhanced expression of Akt
and pim-1 survival genes. HA-mixed ester injection in-
creased H4 histone acetylation and recruited Stro-1 posi-
tive stem cells in the infarcted myocardium, suggesting
that a stimulation of the differentiation potential was also
achieved through this treatment. Nuclear run-off experi-
ments indicated that the action of HA-mixed ester was
modulated at the transcriptional level, although nuclear
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scription. Therefore, it has been hypothesized that retin-
oic acid and butyric acid hydrolyzed from the HA-mixed
ester stimulated DNA transcription. Nevertheless, the mo-
lecular mechanism underlying HA-mixed ester-mediated
responses, as well as the role of HA itself, remain to be
elucidated. The HA-mixed ester was able to enhance car-
diac regeneration in a more relevant manner when associ-
ated with adult stem cells, as described in the following
paragraph.
HA-based hydrogels with a cellular component
HA hydrogels are effective in cardiac repair because they
activate several mechanisms of myocardial regeneration
but also for their ability to serve as a scaffold for stem
cell transplantation. An example of a synergistic action
between a HA-based hydrogel and mesenchymal stem
cells (MSCs) was shown by the above-mentioned mixed
esters of HA with butyric acid and retinoic acid [54].
MSCs isolated from bone marrow, dental pulp, and fetal
membranes of term placenta were first cultured in the
presence of the HA-mixed ester. Angiogenic, mitogenic,
and antiapoptotic factors were upregulated under these
conditions and MSCs were committed into the endothe-
lial and cardiac cell lineages. Early cardiac genes, such as
GATA-4 and Nkx-2.5, as well as sarcomeric genes such
as myosin heavy chain and α-actinin, were significantly
expressed in MSCs isolated from placenta and trans-
planted into infarcted rat hearts, where they increased
capillary density and decreased scar size. Moreover, when
placental MSCs were preconditioned with the HA-mixed
ester, angiogenesis further increased although only a few
engrafted cells stained positive for cardiomyocyte markers.
Since the exposure of MSCs to a CD44 blocking antibody
abrogated the HA-mixed ester-mediated MSC commit-
ment to both cardiac and endothelial phenotypes, it is
conceivable that the involvement of this receptor repre-
sents a necessary step for this process. In addition, the
finding that HA decreased the yield of committed MSCs
in a dose-dependent manner suggests the participation of
a CD44-related uptake system for the HA-mixed ester
entry into the cell.
When the same experiments were performed in the
infarcted pig heart, the injection of placental MSCs pre-
treated with the HA-mixed ester improved both end-
systolic wall thickening and circumferential shortening
of the infarct border zone, and decreased the infarct area
by 40% in comparison to the untreated infarct hearts
[68]. Under this condition, PET showed that both myo-
cardial perfusion and metabolism were improved. This
animal model of MI allowed to underline that the trans-
planted MSCs pretreated with HA-mixed ester seem to
differentiate only as vascular cells but not as cardiomyo-
cytes. By contrast, the protective and regenerative effectson surviving cardiac muscle cells were obtained through
the release of paracrine factors from MSCs. Interestingly,
proteomic analysis of the border zone showed a pheno-
typic homology with healthy cardiac tissue in the group
injected with pretreated placental MSCs. Specifically, the
small-leucin-rich proteoglycan lumican, which contrib-
utes to assembly collagen fibers in the fibrotic scar, was
not upregulated, while mitochondrial respiratory en-
zymes and carbonic anhydrase-I were not downregulated
in the hearts grafted with HA-mixed ester treated MSCs.
The efficacy of the transplantation of mononuclear
bone marrow cells (MNCs), was investigated in MI using
a HA hydrogel as a vehicle [71]. Bone marrow MNCs
are a heterogeneous cell population that consists of
MSCs, hematopoietic stem cells, and endothelial lineage
cells, all of them showing beneficial effects on cardiac
repair [72]. HA of 1,630 kDa MW dissolved at 1% in
PBS formed a hydrogel that provided a favorable micro-
environment for MNC adhesion, proliferation, and vas-
cular differentiation in standard culture condition. The
injection of MNCs embedded in HA hydrogel in the
infarcted heart significantly reduced inflammation, car-
diomyocyte apoptosis, and infarct size. HA hydrogel
improved MNC retention in the injured area and pro-
moted angiogenesis. Based on flow-cytometry analysis,
56% MNCs expressed CD44, while RHAMM expres-
sion was only 0.6%; therefore, CD44 binding with HA
seemed to be responsible, at least in part, of the im-
proved cell adhesion, survival, and differentiation. It is
important to note that MNCs cultured in the presence
of HA secreted more survival and pro-angiogenic factors,
such as FGF-2, HGF, IGF-1, PDGFb, and SFD-1, com-
pared to standard MNCs. This study also highlighted that
cardiac genes such as α-MHC, and cTnI did not increase
in MNCs after exposure to HA, suggesting that HA per se
cannot stimulate stem/progenitor cell differentiation into
the cardiac lineage.
The effect of MNCs suspension in 1% HA hydrogel on
post-MI regeneration was also recently investigated in
mini-pigs by the same Authors [73] and associated with
a significant increase in LV ejection fraction, contractil-
ity, and neovascularization, consistent with a decrease in
infarct size. Interestingly, this combined treatment was
superior in improving myocardial performance than HA
or MNC injection alone. Transplantation of MNCs with
HA also ameliorated cell grafting and differentiation into
the vascular lineage.
Besides bone marrow-derived stem cells, cardiosphere-
derived cells (CDCs) have been largely investigated as
promising cells for cardiac tissue regeneration [74]. In order
to improve acute CDC retention in the myocardium, a
HA-blood hydrogel was synthesized by mixing lysed whole
blood and 16 kDa HA in a 1:1 (v/v) ratio. HA carboxyl
groups were functionalized with N-hydroxysuccinimide
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succinate [75]. This hydrogel (gelation time ~60 s) was
injected intra-myocardially, or applied epicardially, in a
rat model of MI. NHS-activated carboxyl groups of
HA reacted with the primary amines of both blood
and myocardium and formed amide bonds, resulting in
a 3D hydrogel bound to the tissue. CDCs isolated from
rat hearts and cultured in HA-blood hydrogel increased
their survival and rate of proliferation. When CDCs en-
capsulated in this hydrogel were injected in the infarcted
area their retention was enhanced. Indeed, the epicardial
application of the HA-blood hydrogel alone improved LV
ejection fraction. The addition of autologous blood to HA
provided adjunctive adhesion motifs in blood vitronectin
and fibronectin, such as arginine-glycine-aspartate (RGD)
sequence, activating integrin and pro-survival pathways.
Lysed blood also increased the compressive module of the
HA hydrogel resulting in further improvement in cardiac
function [76]. Moreover, the porosity of this blood-HA
hydrogel showed a high swelling ratio that allowed an
enhanced exchange of electrolytes/metabolites and better
cell infiltration.
CDCs isolated from human cardiac biopsies have been
investigated by Marban’s group [77] who employed an in
situ polymerizable hydrogel (Hystem®-C™) as a vehicle
[78]. Hystem®-C™ is a HA and porcine gelatin hydrogel
that can be formulated as a liquid and forms a gel at 37°C
within 20 min. This HA-based hydrogel was crosslinked
using thiol-reactive poly(ethyleneglycol)diacrylate and
covalently linked to collagen to improve cell adhesion.
CDCs, which express multiple collagen-binding integ-
rins (α1, α2, α3) and CD44, were found to be highly
compatible with this hydrogel. In Hystem®-C™ CDCs
acquired a spread morphology, like seen in standard
culture plates, while they remained rounded and more
than 50% died within one week in the base product
without collagen. Additionally, the in vitro migratory
capacity of CDCs, as well as CDC retention, resulted
increased vs. HA alone when using Hystem®-C™ in a
mouse SCID model of MI. These modifications led to
amelioration in cardiac function and to a reduced
degree of adverse remodeling. Thanks to the improved
engraftment, CDC delivery in Hystem®-C™ resulted in
an increased number of new cardiomyocytes and endo-
thelial cells. Therefore, most of these effects were
attributed to the improvement in cell retention and to
the consequent increase in CDC paracrine activity ra-
ther than the differentiation of the grafted cells toward
a cardiomyocyte phenotype. Proofs of the involvement
of Hystem®-C™ alone in cardiac repair were provided
by Abdalla et al. who demonstrated that this hydrogel
was also able to induce a certain degree of neovascu-
larization and to improve cardiac function in a rat
model of MI [79].HA-based patches with a cellular component
Biopolimer-based patches for repairing the infarcted heart
have been manufactured using natural, semi-synthetic, or
fully synthetic materials [80]. Differently from injectable
hydrogels, the mechanical strength of polymeric patches
ensures a superior reinforcement of the infarcted wall as
well as the possibility to build in vitro an engineered car-
diac tissue to be transplanted in the damaged myocar-
dium. Among semi-synthetic polymers used to improve
cardiac regeneration, our group explored the effects of
solid-state structures of HA-based scaffolds. The fine
mechanisms of the interaction of rat MSCs with a HA-
based polymeric support were initially investigated to
evaluate the potential clinical application of these con-
structs [81]. A water insoluble scaffold, HYAFF®11 re-
sulted from the total esterification of the carboxylic
groups of non-woven 200 kDa HA with benzylic alcohol
[50]. The high biocompatibility and biodegradability of
this semi-synthetic biomaterial afforded suitable features
for cell growth and 3D tissue reconstruction, as well as for
the safe transplant of the material to injured body sites
[82,83]. Specifically, the in vitro hydrolytic degradation of
the ester bonds of HYAFF®11 is completed after about
two months in artificial plasma and not later than four
months in biological tissues. Non-woven HYAFF®11
showed 15 μm-average fiber diameter and seeded MSCs
remained viable for a long time, growing on the surface
and in the innermost portions of the scaffold. Early culture
showed MSCs wrapping individual fibers with regularly
spaced focal contacts and fibronexus formation. Despite
the diameter of the fibers was not in the nanoscale range,
it is conceivable that the high number of focal contacts
might regulate fundamental cell functions such as motil-
ity, proliferation, and survival by integrin-mediated cell
signaling. Interestingly, the density of CD90, a putative
marker of mesenchymal stemness, was unaffected after
two weeks of cell culture. Moreover, a polarized cell mem-
brane expression of CD44 was showed in correspondence
to the HYAFF®11-cell contacts, suggesting that these cell
regions can be particularly prone to translate the inter-
action of HA with its receptor into intracellular signaling.
MSCs were able to steadily proliferate on HYAFF®11
and no significant cell loss or degenerative modifica-
tions were found within three weeks of cell culture.
Another consequence of MSCs- HYAFF®11 interaction
was the increased production of proteoglycans, includ-
ing versican and decorin, whose role as repositories of
growth factors and cytokines can also contribute to
tissue regeneration [84].
Non-woven HYAFF®11 appeared as a suitable substrate
also for human EPCs, that showed extensive adhesion and
viability on such a scaffold [85]. Similarly to MSCs, EPCs
easily migrated to and aggregated on the scaffold and
active protein synthesis and features of endothelial
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angiogenic activity.
Since these findings indicated that non-woven HYAFF®11
could be considered as a promising cell vehicle, we tested
the feasibility to graft a MSC/non-woven HYAFF®11 con-
struct in the scar of infarcted rat hearts [86]. Two weeks
after coronary ligation, a small disk of the construct was in-
troduced into a pouch created in the ventricular wall of the
infarcted area. Within two weeks most cells migrated from
the grafted HYAFF®11 towards the border zone close to
coronary vessels and the graft induced angiogenesis and
attenuated the fibrotic process in the infarcted region. To
better understand the mechanisms underlying the specific
roles of MSCs and HYAFF®11 this construct was also
tested in a pre-clinical pig model of MI [87]. The scaffold
adopted was again the total benzyl ester of HA formulated
as a semi-elastic woven mesh to support LV cyclic move-
ments. Autologous bone marrow MSCs were cultured
onto this scaffold for four weeks leading to the formation
of a cardiac patch suitable for transplantation. Female pigs
were subjected to a permanent left anterior descending
coronary artery ligation and scar perfusion was evaluated
by Contrast Enhanced Ultrasound echography eight weeks
after MI. The HYAFF®11/MSC group significantly in-
creased the ratio between the percent peak perfusion
and the time to peak, reaching levels of scar perfusion
comparable with those of the healthy, non-infarcted
hearts. The grafted construct also reduced the infarction-
related inflammation and the foreign reaction against the
graft remained strictly localized around the fibers of the
scaffold. Cardiac tissue positively interacted with the con-
struct by reducing the presence of collagen and increasing
the amount of proteoglycans. Moreover, the cardiomyo-
cytes in the border-zone favorably reacted to the graft and
a lower degree of cellular damage was found. Thus, the
transplantation in the myocardial infarct area of autolo-
gous MSCs supported by a HA-based scaffold restored
blood perfusion in the ischemic area and almost com-
pletely abolished the inflammatory process, showing that
these benefits were superior to those obtained grafting the
scaffold or the MSCs alone. The ability of grafted MSCs to
promote angiogenesis through their paracrine activity
has been described in other models of MI [88]. In syn-
ergy to MSCs, the increase in vessel density stimulated
by HYAFF®11 alone could be related to its gradual
fragmentation into smaller-sized HA olygosaccharides.
The foreign inflammatory reaction localized around
the fibers of the scaffold might have accelerated this
breakdown. On the other hand, the presence of MSCs
attenuated the inflammatory process reactive to MI,
probably owing to the innate immunosuppressive proper-
ties of these cells. Interestingly, the native cardiac tissue
positively interacted with the HYAFF®11/MSCs construct
by reducing the amount of collagen and increasing theamount of proteoglycans in the ECM. A lower degree of
cardiomyocyte damage was observed as well in the border
zone.
Another mesh useful to graft MSCs in the infarcted
myocardium was prepared with HA and silk fibroin [89].
The rationale of this study was that such blends would
allow the combination of the superior mechanical prop-
erties provided by fibroin with the biological features of
HA. The scaffold was prepared by freeze-drying aqueous
solutions of fibroin and HA subsequently incubated in
methanol to induce water insolubility and formation of
microporous structures. MSCs cultured on silk fibroin/
HA scaffolds showed enhanced cellular ingrowth and in-
creased glycosaminoglycan and type-I / type-III collagen
gene expression, as compared to plain silk fibroin scaf-
folds. CD44-blockage treatment decreased MSC growth
rate of about 50% and fibronectin expression was re-
duced [90]. Cardiomyogenesis induced by 5’-azacytidine
on MSCs, documented by GATA-4, Nkx2.5, Tnnt2, and
Actc1 gene expression and upregulation of later cardiac
markers such as cardiotin and connexin 43, could occur
on fibroin/HA patches. Indeed, it is known that this nu-
cleotide analogue can be usefully employed for MSC
commitment into a cardiomyocyte-like phenotype before
transplantation [91,92]. CD44-blockage abolished this
initial commitment toward a cardiac muscle phenotype,
suggesting at least a permissive role of this receptor also
in cardiac specification. Therefore, CD44 influenced pro-
liferation, fibronectin expression, and cardiomyogenic
differentiation in MSCs cultured on fibroin/HA patches.
When implanted into MI rat hearts this cell-engineered
construct remained intact for a long time and attenuated
the local immunological responses, prevented cardio-
myocytes apoptosis, stimulated the secretion of VEGF,
bFGF, and HGF, and improved LV wall thickness, MSC
viability, and myocardial neo-vascularization [93].
Yang et al. deepened the investigations on HA/silk
fibroin-based scaffold introducing a chitosan component
and evaluating its in vitro cardiomyogenic effects on
MSCs [94]. Chitosan is an aminopolysaccharide showing
chemo-attractive properties for growth factors and high
capacity to impact with several compounds, as demon-
strated during bone regeneration [95]. The molecular
weight of HA was 15 kDa, yielding a 1:1:10 (w/w/w)
chitosan/HA/fibroin ratio. Specifically, HA and chito-
san were incorporated to, or co-sprayed with, fibroin
to produce microparticles that were further processed
by mechanical pressing and genipin cross-linking to
produce hybrid cardiac patches. MTT viability assay
demonstrated that MSC expansion and rate of prolifer-
ation on fibroin and fibroin-hybrid patches significantly
exceeded that on traditional culture wells and the expression
of specific cardiac markers significantly increased in MSCs
treated with 5’-azacytidine grown on fibroin/chitosan-HA.
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patches without a cellular component improved LV per-
formance by reducing the inner diameter dilation and
increasing LV wall thickness and fractional shortening,
compared to the untreated rats [96]. Moreover, the
secretion of angiogenic factors and vessel density were
increased in the infarcted region of LV. Thus, it ap-
pears that the presence of chitosan in the HA/fibroin
patch can exert beneficial effects on the damaged myo-
cardium similarly to those described when the HA/fi-
broin scaffold was grafted with MSCs. However, the
molecular mechanisms underlying the in vitro and
in vivo responses mediated by the different scaffolds
containing fibroin, chitosan, and HA, as well as their
single contribution, remain to be elucidated.
Mechanical stretch of HA-based cell constructs
Several experimental evidences have demonstrated that
mechanical forces can modulate intracellular signaling
and gene expression and affect fundamental process
such as cell growth and differentiation [97-99]. Studies
on the effects of cyclic mechanical stress on human car-
diomyocytes grown in a 3D matrix also showed that this
technique promoted a significant increase in cardiomyo-
cyte number size [100], enhanced myofibrillogenesis,
and induced the alignment of collagen fiber bundles in
the ECM [101].
Hybrid cardiac scaffolds with mechanical properties
suitable for in vitro loading studies and in vivo implant-
ation were also constructed from neonatal rat heart cells,
fibrin, and the HA-based woven mesh HYAFF®11 [102].
Early after cell seeding, stiffness was half as high as that
of native heart, whereas ultimate tensile strength, failure
strain, and strain energy density significantly increased
in respect to native heart. Constructs implanted subcuta-
neously in nude rats exhibited a high degree of cardiomyo-
cyte differentiation and blood vessel ingrowth. Although a
significant increase in construct collagen content and
maintenance of stiffness was demonstrated under static
culture conditions, cyclic stretch further increased collagen
biosynthesis in a load-dependent manner. These findings
implied the potential of woven HYAFF®11 for in vivo re-
modeling in response to biochemical and physical factors
mimicking the contracting myocardium.
According to these preliminary results, we then inves-
tigated whether MSCs seeded onto the HYAFF®11 woven
mesh scaffold could be addressed towards a muscle
phenotype via the transfer of a controlled and highly-
reproducible cyclic deformation [103]. The construct
that was obtained after one week of mechanical stretch
showed cells displaying multilayer organization, invading
the 3D mesh of the scaffold, and expressing typical
markers of muscle cells. These effects were due only to
physical cell stimulation, without the need of any otherchemical or genetic manipulation. Therefore, we sug-
gest to explore the efficacy of mechanically-stimulated
MSC/HA-based construct as a reliable engineered myo-
cardial tissue for future investigations on cardiac regener-
ation [104].
Since not long ago, fascinating new discoveries ob-
tained by Chopra et al. [105,106] helped to understand
biological and molecular mechanisms involved in the
interaction between HA and cells, highlighting how HA
is able to change the mechanical response of neonatal
cardiac myocytes in vitro and allow their functional de-
velopment on HA gels. HA matrix by itself is not adhe-
sive for myocytes and often considered to be inert, but
when adhesive ligands, such as fibronectin, collagen I,
laminin, collagen IV, or cadherin are incorporated, they
allow to host well-developed myocytes promoting the
formation of functional sarcomeres. In fact, HA interacts
with cells through its receptors CD44, RHAMM, layilin,
and ICAM-1 and can also bind fibronectin and collagen
VI. Thus, HA alters the integrin-dependent stiffness re-
sponse of cells in vitro suggesting a similar alteration
in vivo, probably modifying the response of cells that
bind the ECM through integrins. It was recently con-
firmed that the presence of long unmodified HA poly-
mers alters the mechanosensing signals mediated by the
activated integrin and induces the acquisition of a pheno-
type that cannot be attained under the same mechanical
conditions by integrin engagement alone [105]. Indeed,
these results provide a rationale to produce a new class of
soft hybrid scaffolds useful in cardiac tissue engineering
and regenerative medicine.
Conclusions
Regeneration of the infarcted region of the myocardium
represents a challenge to reduce the risk of contractile fail-
ure that usually follows the pathological remodeling of the
scarred area. Tissue engineering approaches employing
biomaterials and/or stem cells represent the hope to heal
a damaged heart after MI. HA can be used in its native
form as a vehicle for repairing cells, but more useful deriv-
atives are preferred due to their lower degradability and
increased mechanical strength. When grafted in the in-
farcted heart, HA-based scaffolds improved myocardial
structure and functional parameters by promoting cell
survival, reducing inflammatory reaction, increasing neo-
vascularization, and favoring cardiovascular commitment
of resident or transplanted stem cells (Figure 3), although
to a lower extent. HA-based hydrogels show the advan-
tage to be injected by transcatheter technologies, while
the solid-state counterpart usually needs open-heart sur-
gery. However, care must be taken in modulating hydrogel
density to avoid laceration of myocardial tissue network in
the injected area, especially when cells are simultaneously
delivered. On the other hand, HA in both form of woven
Figure 3 Potential effects of HA-based scaffolds and conveyed stem/progenitor cells on cardiac regeneration after MI. HA-based biomaterial
can be injected as a hydrogel or grafted as a solid mesh providing improvements in left ventricular (LV) structure and functions. Delivered
stem/progenitor cells and/or released growth factors can further increase regeneration efficacy by promoting cell survival, reducing inflammatory
reaction, increasing neoangiogenesis, and favoring resident or transplanted cell differentiation.
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cardial surface reinforcing the cardiac scar and providing
conveyed stem cells for a sustained process of repair. Adult
stem cells transplanted with HA-based scaffolds increased
their viability and improved retention in the grafted region
and a CD44-dependent mechanism has been often invoked
like possible responsible for this benefits. Stem cell differ-
entiation into cardiomyocyte phenotype was also advan-
taged by the presence of HA-based scaffolds, especially
when conjugated with other factors which offer synergistic
effects for cardiac gene expression.
Clinical trials using HA-based materials alone or with
cellular components have been performed in the attemptto obtain a regenerative action mainly as wound healing
and osteo-articular repair. Indeed, most of these studies
underlined the benefits that the HA derivatives, either as
hydrogel or solid mesh, exerted in human diseases such
as venous ulcers [107,108], decubitus ulcers [109], oral
mucosal lesions [110], surgical ablation of nevi/cutane-
ous tumors and cicatritial outcomes [111], talar dome
and knee osteochondral lesions [112,113], and cranial
bone regeneration [114]. So far, no clinical trial started
to verify whether such biomaterial can be useful also to
repair the infarcted myocardium. However, the cumulative
literature here reviewed suggests that HA-based com-
pounds represent a safe biomaterial for cardiac tissue
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improve the survival and the functions of resident and
grafted cells.
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